News Vaxcyte's pneumococcal jab exceeds expectations Shares in Vaxcyte have rocketed on phase 3 trial data for its pneumococcal vaccine VAX-31 that suggests it could take on rivals from Pfizer and MSD.
News Mirum puts Hepcludex in its sights with hep D readout Gilead's Hepcludex was the first drug to be cleared in the US for hepatitis D in May, but a potential rival from Mirum Pharma is already looming.
News Viral disease-carrying Aedes mosquito 'breeding in London' Invasive Aedes mosquitoes and their larvae have been found in London, but the UKHSA says the risk to the public from diseases they can carry is low.
News GSK pushes 'next-generation' mRNA flu shot into phase 3 Buoyed by positive data in a phase 2 trial, GSK will start a phase 3 programme for an mRNA-based flu shot targeting both HA and NA flu antigens.
News Pfizer, Valneva Lyme vaccine starts review in Europe After reporting mixed clinical results in a phase 3 trial, Pfizer and Valneva have filed their Lyme disease vaccine candidate PF-07307405 in the EU.
News SNIPR phage therapy clears MDR infection in first patient A kidney transplant patient with a resistant infection is the first to be treated using a bacteriophage therapy developed by Denmark's SNIPR Biome.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.